Group 1 - Changfei Fiber is currently not engaged in CPO-related business [1] - GCL-Poly Energy does not have the production capacity for "space photovoltaic" products [1] - Zhongke High-tech plans to invest 145 million yuan to implement a new PCB drill needle project with an annual capacity of 30 million units [1] - Samsung Medical's wholly-owned subsidiary is expected to win a bid for a 321 million yuan project from Southern Power Grid [1] - Solar Energy's subsidiary plans to acquire 100% equity of Jinhua Windling [1] - SMIC expects a net profit of 1.223 billion yuan for Q4 2025, a year-on-year increase of 23.2% [1] - Xiying Network has repurchased 2.061 million shares for the first time [1] - Runbei Aerospace's controlling shareholder plans to reduce holdings by no more than 3% [1] - Zhen'an Technology plans to raise no more than 740 million yuan through a private placement [1] - Jiangsu New Energy plans to issue convertible bonds to raise no more than 1.24 billion yuan [1] Group 2 - Hengdian Film and Television may apply for a trading suspension if its stock price continues to rise abnormally [1] - Kangda New Materials' subsidiary plans to invest in a project with an annual output of 30,000 tons of polyarylether [1] - Zhongchuan Hanguang plans to build a comprehensive materials park [1] - Huichuan Technology expects a net profit growth of 16%-26% for 2025 [1] - Yutong Technology plans to acquire 51% of Huayan Technology [1] - Weilan Bio's subsidiary plans to acquire 50% equity of Aidi Meng Weilan for 47 million yuan [1] - Kaiying Network has repurchased 2.061 million shares for the first time [2] - Wushang Group's Dazhi Yintai plans to reduce holdings by no more than 3% [2] - Newhan New Materials plans to raise no more than 1 billion yuan for an annual production of 8,100 tons of high-performance resin [2]

智通财经APP讯，东阿阿胶(000423.SZ)发布公告，公司拟以14.85亿元(其中固定资产投资14.21亿元，铺 底流动资金0.64亿元)的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能 性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 公司董事会决议授权管理层具体推进落实该项目，包括但不限于进一步完善规划设计、细化投资测算、 建设施工，以及办理其他与本投资事项相关的一切事宜。 ...

东阿阿胶表示，项目建设符合东阿阿胶健康消费品业务发展的迫切需要。健康消费品业务具有需求多样 化、产品迭代快等特点，对研发、质量、敏捷供应链等具有更高要求，公司现有产业园存在扩产面积受 限、主要产线面临产能瓶颈等问题，无法满足健康消费品快速升级迭代等发展需求。自建厂房有助于构 建东阿阿胶健康消费品领域核心优势。 北京商报讯（记者 丁宁）2月10日晚间，东阿阿胶（000423）发布公告称，公司拟以14.85亿元（其中固 定资产投资14.21亿元，铺底流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食 同源食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商 分拣及药品成品仓储等。 ...

北京商报讯（记者 王寅浩 宋雨盈）2月10日，东阿阿胶发布公告称，公司拟以14.85亿元（其中固定资 产投资14.21亿元，铺底流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源 食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣 及药品成品仓储等。 ...

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced that its non-wholly owned subsidiary, Dong'e Ejiao (东阿阿胶), has decided to invest in and construct a health consumer goods industrial park, which will enhance its production capabilities and support the growth of its health consumer goods business [1][2]. Group 1: Investment and Construction Details - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing, logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1]. - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, which will include production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1]. - The total investment for the project is estimated to be around RMB 1.485 billion, with fixed asset investment amounting to approximately RMB 1.421 billion and working capital of about RMB 64 million [1]. Group 2: Strategic Importance - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine [2]. - The project is designed to establish a dual-driven business growth model combining pharmaceuticals and health consumer goods, fostering a second growth curve while addressing the urgent needs for the development of health consumer goods [2]. - The existing industrial park faces limitations in expansion and capacity bottlenecks, which hinder the ability to meet the rapid upgrades and iterations in health consumer goods, making the new construction essential for maintaining competitive advantages [2].

Group 1 - The company Huaren Pharmaceutical (03320) announced that its non-wholly owned subsidiary Dong'e Ejiao (000423.SZ) has decided to invest in and construct a health consumer goods industrial park [1] - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing and logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1] - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, including production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1] Group 2 - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine and establish a dual-driven business growth model of pharmaceuticals and health consumer goods [2] - The existing industrial park of Dong'e Ejiao faces limitations in expansion area and capacity bottlenecks in major production lines, which cannot meet the rapid upgrading and iteration needs of health consumer products [2] - Building the new facilities will help Dong'e Ejiao establish a core advantage in the health consumer goods sector, with a focus on Ejiao series products, enhancing brand regional recognition, and strengthening core competitiveness [2]

格隆汇2月10日丨东阿阿胶(000423.SZ)公布，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底 流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性 食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 ...

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced that its non-wholly owned subsidiary, Dong'e Ejiao Co., Ltd. (listed on Shenzhen Stock Exchange, stock code: 000423), has decided to invest in and construct a health consumer products industrial park [1] Group 1 - The proposed health consumer products industrial park is expected to include manufacturing facilities for health consumer products such as pharmaceuticals, traditional food, health supplements, and functional foods [1] - The industrial park will also feature supporting warehousing and logistics facilities, a quality inspection center, a new product incubation center, e-commerce sorting, and finished product warehouses [1]

东阿阿胶公告，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底流动资金0.64亿元）的自有资 金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性食品等健康消费品的生产与配 套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。项目总用地面积40.68万平方 米，建设周期约为22个月。 ...

东阿阿胶股份有限公司 内部审计制度 （2026 年 2 月 9 日 经公司第十一届董事会第十七次会议审议通过） 第一章 总则 第一条 为了规范东阿阿胶股份有限公司（以下简称"东阿阿胶" 或"公司"）及各子公司的内部审计工作，有效贯彻落实上级单位等 相关管理要求，不断规范经营行为、防范和降低经营风险、提升经营 效率和效果，实现高质量发展，根据《中华人民共和国审计法》《审 计署关于内部审计工作的规定》《关于深化中央企业内部审计监督工 作的实施意见》《中国内部审计准则》等法律法规规定，制定本制度。 第二条 本制度适用于东阿阿胶及下属公司（以下简称"各级单 位"）。 第三条 本制度所称内部审计，是指东阿阿胶内部独立、客观的 监督、评价和建议活动，通过运用系统、规范的方法，审查评价重大 决策部署、政策措施、监管要求落实、战略执行、法律法规遵循、经 济活动、风险管理、内部控制、财务收支、企业文化等情况，总结管 理实践，揭示问题和风险，提出改善建议，督促整改落实，推动公司 战略落地、规范经营、完善治理，实现高质量可持续发展。 第四条 内部审计的宗旨是保障战略、防范风险、创造价值。东 阿阿胶各级单位应当自觉配合内部审计机构， ...